These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31103265)

  • 21. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
    Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
    J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
    Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
    Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
    Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
    Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
    Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
    Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
    Qiu HB; Yang K; Yu HY; Liu M
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lnc-NTF3-5 promotes osteogenic differentiation of maxillary sinus membrane stem cells via sponging miR-93-3p.
    Peng W; Zhu SX; Wang J; Chen LL; Weng JQ; Chen SL
    Clin Implant Dent Relat Res; 2018 Apr; 20(2):110-121. PubMed ID: 29106055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells.
    Zhu M; Huang Y; Tang J; Shao S; Zhang L; Zhou Y; He S; Wang Y
    Exp Hematol; 2020 Jan; 81():50-59. PubMed ID: 31899217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
    Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
    J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
    Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
    Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
    J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of XIST facilitates cell proliferation, invasion and suppresses cell apoptosis by reducing radio-sensitivity of glioma cells via miR-329-3p/CREB1 axis.
    Wang YP; Li HQ; Chen JX; Kong FG; Mo ZH; Wang JZ; Huang KM; Li XN; Yan Y
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3190-3203. PubMed ID: 32271437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 38. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
    Wu Y; Wang H
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.